The Non Ergot D2-Dopamine Agonist CV 205–502 Decreases Growth Hormone Concentrations in Acromegalic Patients
Author:
Publisher
Informa UK Limited
Subject
Endocrinology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1080/07435809409035856
Reference7 articles.
1. In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H]CV 205–502
2. Prolactinom-Behandlung mit einem neuen Dopaminagonisten
3. The Efficacy and Tolerability of CV 205–502 (a Nonergot Dopaminergic Drug) in Macroprolactinoma Patients and in Prolactinoma Patients Intolerant to Bromocriptine
4. Changes in Plasma Growth Hormone Levels in Normal and Acromegalic Subjects Following Administration of 2-Bromo-α-Ergocryptine
5. Stimulation of Growth Hormone Release in Man by the Potent D2-Dopamine Agonist CV 205-502: Comparison of Responses to Intravenous and Oral Administration*
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Medical Therapy of Acromegaly;International Journal of Endocrinology;2012
2. Stimulants and growth in children with attention-deficit/hyperactivity disorder;Medical Hypotheses;2011-07
3. A Risk-Benefit Assessment of Octreotide in the Treatment of Acromegaly;Drug Safety;1997-11
4. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly;European Journal of Endocrinology;1995-08
5. Chapter 31. To Market, To Market – 1994;Annual Reports in Medicinal Chemistry;1995
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3